Lipid Nanoparticles, Key Component of COVID-19 mRNA Vaccines
Vaccines against COVID-19 have been developed with unprecedented speed. In particular, mRNA vaccines — a technology already in clinical trials for other infectious diseases, such as influenza — have shown impressive efficacy in clinical trials.
mRNA vaccines rely on the delivery of mRNA into the cytoplasm of host cells, where it can be transcribed into antigenic proteins to trigger the production of neutralizing antibodies. However, mRNA is three to four orders of magnitude larger than molecules that readily diffuse into cells; in addition, the dense negative charge of mRNA electrostatically repulses the anionic cell membrane, preventing its uptake. Therefore, mRNA vaccines require a delivery vehicle that not only protects the nucleic acid from degradation but allows the mRNA to get into cells.
BioNTech/Pfizer’s and Moderna’s mRNA vaccines both use lipid nanoparticles as mRNA carriers. The impressive speed at which these vaccines could be developed is partly owed to the fact that nucleic acid delivery by lipid nanoparticles has long been investigated and optimized by the nanomedicine community, who thoroughly studied lipid nanoparticle chemistry, structure, surface, injection routes, uptake, endosomal escape, cargo release, dosage, clearance and, importantly, safety.
Owing to their size and properties, lipid nanoparticles are taken up by cells via endocytosis, and the ionizability of the lipids at low pH (likely) enables endosomal escape, which allows release of the cargo into the cytoplasm. In addition, lipid nanoparticles usually contain a helper lipid to promote cell binding, cholesterol to fill the gaps between the lipids, and a polyethylene glycol (PEG) to reduce opsonization by serum proteins and reticuloendothelial clearance. The relative amounts of ionizable lipid, helper lipid, cholesterol and PEG substantially affect the efficacy of lipid nanoparticles, and need to be optimized for a given application and administration route.
It was a long road to optimizing lipid nanoparticle formulations for nucleic acid delivery. To achieve clinical efficacy, every aspect of the lipid nanoparticle formulation had to be optimized, and more than 300 ionizable lipids had to be screened. Furthermore, all key steps of the lipid nanoparticle journey in the body had to be understood before clinical trials could begin. This knowledge has certainly contributed to the rapid development of COVID-19 mRNA vaccines.
From a materials science perspective, the success of lipid nanoparticle mRNA vaccines is exciting and important, as it underlines the value of materials science for medical advances and motivates further fundamental and applied nanoparticle research, which will hopefully be reflected in future funding cycles.
Huateng Pharma, a professional PEG supplier, is dedicated to manufacturing and supplying a wide range of PEG derivatives. Lipid nanoparticles is a key component of COVID-19 mRNA vaccines. We can supply below PEG products which are excipients used in COVID-2019 vaccine.
1.ALC-0159, mPEG-N,N-Ditetradecylacetamide, CAS No. 1849616-42-7
2.mPEG-DMG, CAS NO. 160743-62-4
5.mPEG-OH, CAS NO. 9004-74-4
Hunan Huateng Pharmaceutical Co. Ltd.
Telephone: +86 731 89916275
Fax: +86 0731-82251112-818
Human Huateng Pharmaceutical Co., Ltd. is a leading and professional manufacturer which can provide pharmaceutical intermediates, PEG derivatives, biochemical reagents, APIs, Vitamin D Derivatives and so on.
Huateng Pharma is committed to providing cost-effective pharmaceutical products and services to customers around the world with the belief of “Strive for the Human Health".
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lipid Nanoparticles, Key Component of COVID-19 mRNA Vaccines here
News-ID: 2299103 • Views: 509
More Releases from Hunan Huateng Pharmaceutical Co. Ltd.
Existing Drugs May Inhibit SARS-CoV-2 Virus
The COVID-19 pandemic has caused more than 600,000 deaths in the United States since the start of 2020 and more than 4 million globally. The search for effective treatments against the disease are ongoing, and one hurdle is that SARS-CoV-2, the virus that causes COVID-19, has a number of tricks up its molecular sleeve when it comes to infecting people. In a recent study published in Nature Communications Biology, researchers from
Disguised Protein May Be A New Target For Cancer Immunotherapy
Researchers at the Francis Crick Institute have identified a protein that helps tumors evade the immune system and, in certain types of cancers, is linked to a poorer chance of survival. The protein could become a target for future cancer treatments. A crucial part of the immune system's response to cancer is a group of white blood cells, called CD8+ T-cells, which kill tumor cells. Before they launch their anti-tumor response,
Most People Are Susceptible To Type 2 Diabetes
A recent study from scientists at Indiana University School of Medicine, the University of Michigan and Case Western Reserve University has determined that the sequence of insulin has become entrenched at the edge of impaired production, an intrinsic vulnerability unmasked by rare mutations in the insulin gene causing diabetes in childhood. The study exploits biophysical concepts and methods to relate protein chemistry to the emerging field of evolutionary medicine. Insulin is
Potential of Anti-influenza Drugs For The Control of High Pathogenicity Avian In …
Scientists have discovered a route of introduction for High Pathogenicity Avian Influenza Virus (HPAIV) H5N8 into Japan and, in parallel, have investigated the potential of two human anti-influenza drugs for the control of HPAI in birds. Since October 30, 2020, there have been over 30 recorded outbreaks of High Pathogenicity Avian Influenza (HPAI) in domestic poultry and wild fowl in Japan. This outbreak was caused by the influenza A virus H5N8,
More Releases for PEG
PEG-12 Dimethicone Market: Competitive Dynamics & Global Outlook 2025
LP INFORMATION recently released a research report on the PEG-12 Dimethicone market analysis, which studies the PEG-12 Dimethicone's industry coverage, current market competitive status, and market outlook and forecast by 2025. Global “PEG-12 Dimethicone Market 2020-2025” Research Report categorizes the global PEG-12 Dimethicone market by key players, product type, applications and regions,etc. The report also covers the latest industry data, key players analysis, market share, growth
PEG-10 Dimethicone Market: Competitive Dynamics & Global Outlook 2025
LP INFORMATION recently released a research report on the PEG-10 Dimethicone market analysis and elaborate the industry coverage, current market competitive status, and market outlook and forecast by 2025. Moreover, it categorizes the global PEG-10 Dimethiconemarket by key players, product type, applications and regions,etc. The main objective of this market research is to help the readers understand the structure of PEG-10 Dimethiconemarket, market definition, overview, industry opportunities and trends, investment
Application of PEG In Click Chemistry
Polyethylene glycol (PEG) is a biocompatible, synthetic, hydrophilic polyether compound that has many applications, mostly in the medical industry, but also in the chemical and industrial sectors. The synthesis of PEG is done by polymerizing ethylene oxide, the main ingredient in antifreeze, using a ring-opening technique, which allows for PEGs of a range of molecular weights and molecular weight distributions to be constructed. This range in weights is what makes
What Are PEG Linkers?
Hydrophilic poly(ethylene glycol) or PEG-linkers are particularly attractive as a linker for conjugation. Water solubility, lack of toxicity; low immunogenicity and well defined chain lengths and molecular weights are specific characteristics of PEG moieties relevant to pharmaceutical applications. Hydrophilic linkers The link between the antibody and the cytotoxic agent plays a critical role in development of antibody-drug conjugates. The nature of the linker can significantly affect the potency, selectivity, and the pharmacokinetics of
Biochempeg developed a series of PEG compounds used for Semaglutide
Type 2 diabetes is the most common form of diabetes. Semaglutide is an agonist of glucagon-like peptide-1 (GLP-1) receptor that is developed to treat type 2 diabetes. It reduces blood sugar via increasing the production of insulin. Biochempeg has developed and can supply some key intermediates of Semaglutide. Semaglutide(trade names: Rybelsus,Ozempic) is a medication for the treatment of type 2 diabetes. It was discovered in 2012, by a team of researchers
Global PEG Stearate Market Huge Growth Opportunity between 2020-2025
LP INFORMATION recently released a research report on the PEG Stearate market analysis, which studies the PEG Stearate's industry coverage, current market competitive status, and market outlook and forecast by 2025. Global "PEG Stearate Market 2020-2025" Research Report categorizes the global PEG Stearate market by key players, product type, applications and regions,etc. The report also covers the latest industry data, key players analysis, market share, growth